HAS Group announces successful Swissmedic inspection of the new ADC Suite at Cerbios-Pharma SA
Lugano, Switzerland – 28.08.2026
HAS Group has successfully completed the Swissmedic inspection process for the new ADC Suite at Cerbios‑Pharma SA, confirming the readiness of its enhanced ADC manufacturing capabilities.
The new ADC facility is fully equipped with single-use equipment including chromatography and was designed to host any type of conjugation technology enabling high flexibility in terms of batch size and manufacturing process including handling of light sensitive products. Moreover, the adopted containment level, allows the manipulation of all commonly used linker-payloads with multiple Occupational Exposure Levels.
In terms of capacity, the suite is equipped with single use reactors, with scale up to 500 L specifically designed for large‑scale ADC production, significantly enhancing Cerbios’ capacity to support late‑stage and commercial programs.
Representing a key milestone within Cerbios’ expanding ADC platform, this asset supports integrated services from early development to commercial manufacturing within a highly controlled and compliant environment.
Furthermore, this expansion reinforces Cerbios’ commitment to the highest standards of quality, compliance, and operational excellence in the development and manufacturing of advanced bioconjugates, including ADCs.
“We are very pleased with this outcome, which demonstrates the strength of our quality systems and the commitment of HAS Group. This achievement further reinforces our position as a reliable and trusted CDMO partner for ADCs.” said Waldo Mossi.
As a result of HAS Group’s investments plan in advanced technologies and infrastructure to support the growing demand for next‑generation therapeutics, additional facilities are currently being constructed to further increase the capacity for small molecules, linker-payloads and ADCs
About the HAS Group:
HAS Healthcare Advanced Synthesis is part of the HAS Group, an integrated CDMO platform established in 2025 through the acquisition of Cerbios‑Pharma SA. Rooted in decades of Swiss precision and built on more than forty years of combined experience, the HAS Group brings together advanced chemical and biological expertise within a single, fully integrated organization.
With a robust portfolio of established APIs and pharmaceutical products, the Group delivers innovative solutions across highly specialized technologies, including highly Potent and complex small molecules and Antibody‑Drug Conjugates (ADCs). This foundation reflects a long‑term vision driven by scientific excellence, quality, and strong family values.
We unite complementary capabilities in chemical and biological development, specializing in APIs, HPAPIs, anticancer compounds, linker‑payloads, and ADCs. Our end‑to‑end solutions guide projects from early‑phase development through commercial supply, leveraging multiple GMP‑certified sites across Switzerland. We combine scientific excellence with strategic agility to accelerate our partners’ success.
Whether advancing early‑stage research or scaling for global markets, HAS Group is your trusted partner to innovate, manufacture, and deliver.
For more information:
Press Office:
Giacomo Braglia
Tel: +41 (0) 91 873 94 00